XML 49 R32.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Common Stock (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2017
Equity [Abstract] |
Summary of Fair Value of Option Awards | The estimated fair value of stock options granted in the respective periods was determined using the Black-Scholes option pricing model using the following weighted average assumptions:
|  | 2017 |  |
Risk-free interest rates |  |  | 1.95 | % |
Expected dividend yield |  |  | 0 | % |
Expected life |  | 6 years |  |
Expected volatility |  |  | 86.06 | % |
Summary of Share-Based Compensation Expense | The results for the periods set forth below included stock-based compensation expense in the following expense categories of the consolidated statements of loss (in thousands):
|  | Year ended
|  | December 31,
|  | 2017 |  |
Research and development |  | $ | 107 |  |
General and administrative |  |  | 241 |  |
Total stock-based compensation |  | $ | 348 |  |
Summary of Stock Options Activity | Stock option transactions and the number of stock options outstanding are summarized below:
|  | Number of |  |  | Weighted |
|  | Optioned |  |  | Average |
|  | Common |  |  | Exercise |
|  | Shares |  |  | Price |
Balance, January 1, 2017 |  | $ | — |  |  | $ | — |
Additions from OncoGenex Plan |  |  | 113,451 |  |  |  | 96.38 |
Granted |  |  | 1,052,200 |  |  |  | 2.89 |
Expired |  |  | (19,543 | ) |  |  | 114.53 |
Exercised |  |  | — |  |  |  | — |
Forfeited |  |  | (30,461 | ) |  |  | 92.72 |
Balance, December 31, 2017 |  |  | 1,115,647 |  |  | $ | 7.99 |
Summary of Stock Options Outstanding Regarding Number of Common Shares Issuable upon Exercise of Outstanding Options | (1) Number of common shares issuable upon exercise of outstanding options:
|  |  |  |  |  |  |  |  |  | Weighted- |
|  |  |  |  |  |  |  |  |  | Average |
|  |  |  |  |  |  |  |  |  | Remaining |
|  |  |  |  |  | Weighted- |  |  | Contractual |
|  |  |  |  |  | Average |  |  | Life |
Exercise Prices |  | Number of Options |  |  | Exercise Price |  |  | (in years) |
$2.89 - $6.95 |  |  | 1,052,200 |  |  | $ | 2.89 |  |  |  | 9.58 |
$6.96 - $15.73 |  |  | 4,090 |  |  |  | 11.00 |  |  |  | 8.40 |
$15.74 - $20.63 |  |  | 17,983 |  |  |  | 20.46 |  |  |  | 7.38 |
$20.64 - $37.35 |  |  | 6,452 |  |  |  | 31.53 |  |  |  | 6.76 |
$37.36 - $128.64 |  |  | 2,451 |  |  |  | 84.08 |  |  |  | 5.75 |
$128.65 - $130.57 |  |  | 8,905 |  |  |  | 129.69 |  |  |  | 6.20 |
$130.58 - $134.81 |  |  | 6,450 |  |  |  | 131.45 |  |  |  | 5.19 |
$134.82 - $143.88 |  |  | 5,927 |  |  |  | 142.41 |  |  |  | 4.36 |
$143.89 - $185.85 |  |  | 7,019 |  |  |  | 172.70 |  |  |  | 3.01 |
$185.86 - $245.08 |  |  | 4,170 |  |  |  | 237.60 |  |  |  | 2.21 |
|  |  | 1,115,647 |  |  | $ | 7.99 |  |  |  | 9.37 |
Summary of Stock Options Outstanding Regarding Number of Common Shares Issuable upon Exercise of Vested Options | (2) Number common shares issuable upon exercise of vested options:
|  |  |  |  |  |  |  |  |  | Weighted- |
|  |  |  |  |  |  |  |  |  | Average |
|  |  |  |  |  |  |  |  |  | Remaining |
|  |  |  |  |  | Weighted- |  |  | Contractual |
|  |  |  |  |  | Average |  |  | Life |
Exercise Prices |  | Number of Options |  |  | Exercise Price |  |  | (in years) |
$2.89 - $6.95 |  |  | 3,644 |  |  | $ | 2.89 |  |  |  | 9.58 |
$6.96 - $15.73 |  |  | 4,090 |  |  |  | 11.00 |  |  |  | 8.40 |
$15.74 - $20.63 |  |  | 14,883 |  |  |  | 20.46 |  |  |  | 7.38 |
$20.64 - $37.35 |  |  | 5,432 |  |  |  | 31.25 |  |  |  | 6.77 |
$37.36 - $128.64 |  |  | 2,451 |  |  |  | 84.08 |  |  |  | 5.75 |
$128.65 - $130.57 |  |  | 8,758 |  |  |  | 129.69 |  |  |  | 6.20 |
$130.58 - $134.81 |  |  | 6,450 |  |  |  | 131.45 |  |  |  | 5.19 |
$134.82 - $143.88 |  |  | 5,927 |  |  |  | 142.41 |  |  |  | 4.36 |
$143.89 - $185.85 |  |  | 7,019 |  |  |  | 172.70 |  |  |  | 3.01 |
$185.86 - $245.08 |  |  | 4,170 |  |  |  | 237.60 |  |  |  | 2.21 |
|  |  | 62,824 |  |  | $ | 91.79 |  |  |  | 5.95 |
Summary of Restricted Stock Unit Award Activity | The following table summarizes our restricted stock unit award activity during the year ended December 31, 2017:
|  |  |  |  |  | Weighted |
|  | Number |  |  | Average |
|  | of |  |  | Grant Date |
|  | Shares |  |  | Fair Value |
Balance, January 1, 2017 |  |  | - |  |  | $ | - |
Additions from OncoGenex Plans |  |  | 10,527 |  |  |  | 41.12 |
Granted |  |  | 205,100 |  |  |  | 2.89 |
Released |  |  | (5,464 | ) |  |  | 44.25 |
Forfeited or expired |  |  | (3 | ) |  |  | 25.37 |
Balance, December 31, 2017 |  |  | 210,160 |  |  | $ | 3.73 |
Summary of Outstanding Warrants | The following is a summary of outstanding warrants to purchase common stock at December 31, 2017:
|  | Total |  |  |  |  |  |  |
|  | Outstanding |  |  | Exercise |  |  |
|  | and |  |  | price per |  |  |
|  | Exercisable |  |  | Share |  |  | Expiration Date
(1) Series A Warrants issued in July 2014 financing |  |  | 252,721 |  |  |  | 44.000 |  |  | July 2019
(2) Series B Warrants issued in July 2014 financing |  |  | 60,933 |  |  |  | 44.000 |  |  | July 2019
(3) Series A-1 Warrants issued in April 2015 financing |  |  | 21,748 |  |  |  | 26.400 |  |  | October 2020
(4) Warrants issued in September 2017 financing |  |  | 82,237 |  |  |  | 3.496 |  |  | March 2023
Summary of Fair Value of Warrants Issued |
|  | As of |
|  | December 31, |
Series A and Series B Warrant Valuation Assumptions |  | 2017 |  |  | 2016 |
Risk-free interest rates |  |  | 1.82 | % |  |  | — |
Expected dividend yield |  |  | 0 | % |  |  | — |
Expected life |  | 1.50 years |  |  |  | — |
Expected volatility |  |  | 86 | % |  |  | — |
Computation of Basic and Diluted Net Loss Attributable to Common Shareholders Per Share | The following table presents the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share and share amounts):
|  | Years ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Numerator |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (10,583 | ) |  | $ | (1,234 | ) |  | $ | (828 | )
Denominator |  |  |  |  |  |  |  |  |  |  |  |
Weighted average number of common shares outstanding |  |  | 4,794,421 |  |  |  | 21,230 |  |  |  | 21,230 |
Basic and diluted net loss per common share |  | $ | (2.21 | ) |  | $ | (58.13 | ) |  | $ | (39.00 | )

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants issued, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends and (d) risk-free rate(s). + References No definition available. + Details
Name: | achv_FairValueOfWarrantsIssuedTableTextBlock
Namespace Prefix: | achv_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of share based compensation shares vested under stock option plans by exercise price range. + References No definition available. + Details
Name: | achv_ScheduleOfShareBasedCompensationSharesVestedUnderStockOptionPlansByExercisePriceRangeTableTextBlock
Namespace Prefix: | achv_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the change in stock options. + References No definition available. + Details
Name: | us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=96867065&loc=d3e5047-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration